Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration

描述（由申请人提供）：CNS轴突再生的主要障碍是存在与髓鞘碎片和神经胶质瘢痕相关的生长抑制蛋白。中枢神经系统损伤后的功能恢复需要克服这种抑制。最近的研究表明，cAMP的变化，沿着PKC、EGFR和RhoA活性的增加，是抑制性信号传导的重要方面。然而，我们仍然缺乏知识的数量/身份的抑制蛋白与抑制损伤部位，详细的信号传导机制所采用的抑制性受体，和细胞类型特异性反应受损的轴突。此外，存在与当前药理学策略相关的问题，包括缺乏特异性、不确定的毒性和靶向具有多效性功能的途径。为了克服这些困难，我们已经启动了一个基于表型的无偏筛选的一种新的化合物库选择其有利的化学性质，而不是已知的生物功能。该筛选基于化合物增加用抑制性髓鞘底物激发的CNS神经元的神经突生长的能力。初步结果已经产生了4种能够强烈增加神经突生长的“命中化合物”。随后的研究表明，命中化合物a）作用于不同的神经元类型，B）选择性地克服抑制而不是促进生长，c）是高度有效的，d）在与损伤相关的不同测定中克服抑制，e）不影响cAMP水平、PKC活性或EGFR活化，f）改变微管动力学，和g）促进体内再生。由于这些化合物是有效的和选择性的，并且可以通过新的机制起作用，因此它们是治疗开发和再生抑制机制研究的令人兴奋的候选者。该方案是1）研究4种命中化合物的信号传导机制和蛋白靶点，2）检查1种命中化合物在体内促进脊髓损伤或视神经挤压后再生的能力，以及3）在新型抑制性（蛋白聚糖）底物上筛选完整的4000种化合物文库。这些实验可以为再生抑制提供关键见解，并为CNS损伤的新方法铺平道路。公共卫生相关性：所提出的实验将研究新化合物促进再生的作用机制，并阐明它们在CNS损伤后增加轴突再生的能力。

DESCRIPTION (provided by applicant): A major barrier to regeneration of CNS axons is the presence of growth-inhibitory proteins associated with myelin debris and the glial scar. Functional recovery after CNS injury requires that this inhibition be overcome. Recent studies suggest that changes in cAMP, along with increases in PKC, EGFR, and RhoA activities, are important aspects of inhibitory signaling. However, we still lack knowledge about the number/identity of inhibitory proteins associated with inhibition at injury sites, the detailed signaling mechanisms employed by inhibitory receptors, and the cell type-specific responses of damaged axons. Further, there are problems associated with current pharmacological strategies, including lack of specificity, uncertain toxicities, and the targeting of pathways with pleiotrophic functions. To overcome these difficulties, we have initiated a phenotype-based unbiased screen of a novel chemical compound library chosen for its favorable chemical properties rather than known biological function. The screen is based on the ability of compounds to increase neurite outgrowth from CNS neurons challenged with inhibitory myelin substrates. Initial results have produced 4 "hit compounds" capable of strongly increasing neurite growth. Subsequent investigations indicate that the hit compounds a) act on different neuronal types, b) selectively overcome inhibition rather than promote growth, c) are highly potent, d) overcome inhibition in distinct assays relevant to injury, e) do not affect cAMP levels, PKC activity, or EGFR activation, f) alter microtubule dynamics, and g) promote regeneration in vivo. Because the compounds are potent and selective, and may act through novel mechanisms, they are exciting candidates for therapeutic development and for mechanistic studies of regeneration inhibition. The proposal is to 1) investigate the signaling mechanisms and protein targets of the 4 hit compounds, 2) examine the ability of 1 hit compound to promote regeneration after spinal cord injury or optic nerve crush in vivo, and 3) screen the full 4000 compound library on a novel inhibitory (proteoglycan) substrate. These experiments could provide key insights into regeneration inhibition, and pave the way for a novel approach to CNS injury. PUBLIC HEALTH RELEVANCE: The proposed experiments will investigate the mechanisms of action of novel compounds promoting regeneration, and elucidate their ability to increase axonal regrowth after CNS injury.